Borderline ovarian tumors typically affect young women, making fertility preservation a major consideration in clinical management. Although fertility-sparing surgery is considered the standard of care for borderline ovarian tumors regardless of disease stage, its oncologic safety remains an active subject of debate.
In addition to questions surrounding surgical preservation, the therapeutic role and clinical benefit of adjuvant chemotherapy in this disease setting remain unclear and controversial within the medical literature.
The published report details the case of a 37-year-old patient diagnosed with a FIGO stage IIIB micropapillary borderline ovarian tumor involving both ovaries. Histopathologic assessment identified invasive implants on the surface of the right ovary and fallopian tube, along with diffuse non-invasive desmoplastic implants across other peritoneal sites, and initial debulking fertility-sparing surgery resulted in pelvic residual disease.
Given the patient’s advanced disease stage, specific histopathologic features, and reproductive goals, clinical teams administered six cycles of adjuvant carboplatin chemotherapy. Following the completion of chemotherapy, the patient decided not to pursue further fertility preservation, leading surgeons to proceed with completion surgery.
Pathological examination from the completion surgery confirmed a complete pathological response with no microscopic residual disease. The authors concluded that this outcome is noteworthy and hypothesis-generating, documenting a complete response in an advanced-stage case where the efficacy of chemotherapy remains controversial.
The case report was authored by researchers from the Department of Medicine and Surgery at the University of Milano-Bicocca and the Fondazione IRCCS San Gerardo dei Tintori in Monza, Italy. The article was published in the Gynecological Oncology section of the journal. The manuscript was received in March 2026 and accepted for publication in October 2026. Tommaso Bianchi is listed as the corresponding author for the study. The article is distributed under a Creative Commons Attribution License, allowing for open access and reproduction provided the original authors and journal are credited.
Subject of Research: Adjuvant carboplatin chemotherapy response in advanced-stage borderline ovarian tumors
Article Title: Any role for adjuvant chemotherapy in advanced-stage borderline ovarian tumors? A case report and review of the literature
Article References: Corti, J., Bianchi, T., Jaconi, M., Pecis Cavagna, G., Aiolfi, T., Grassi, T., Trezzi, G., Chiari, S., Casiraghi, A., Lissoni, A. A., & Fruscio, R. (2026). Any role for adjuvant chemotherapy in advanced-stage borderline ovarian tumors? A case report and review of the literature. Frontiers in Oncology, 16, Article 1822209. https://doi.org/10.3389/fonc.2026.1822209
Image Credits: AI Generated
DOI: 10.3389/fonc.2026.1822209
Keywords: borderline ovarian tumors, carboplatin, adjuvant chemotherapy, fertility-sparing surgery, micropapillary serous BOT, complete pathological response, FIGO stage IIIB, gynecological oncology, invasive implants, non-invasive desmoplastic implants, pelvic residual disease, peritoneal implants, completion surgery, fertility preservation, debulking surgery, fallopian tube
News Source: Nathaniel Bowman. (November 19, 2026). Case Report Documents Complete Chemotherapy Response in Advanced Borderline Ovarian Tumor. Scienmag.



